Expanded FDA Lab Oversight May Result In Relaxed Regs For Some Test Kits
This article was originally published in The Gray Sheet
Executive Summary
FDA is considering changing how it regulates in vitro diagnostic test kits, perhaps down-classifying some kits, as it prepares to assume oversight of laboratory-developed-test services
You may also be interested in...
Clinical Labs Join Medical Device User Fee Negotiations
The clinical lab community will for the first time join traditional device and imaging equipment makers in FDA user fee reauthorization talks, but members are not quite ready to concede to agency oversight.
Clinical Labs Join Medical Device User Fee Negotiations
The clinical lab community will for the first time join traditional device and imaging equipment makers in FDA user fee reauthorization talks, but members are not quite ready to concede to agency oversight.
AdvaMed Compiles List Of Tests That Should Be Exempt From FDA Review
Device trade group AdvaMed has given FDA a list of 30 lower-risk diagnostic tests that it says should be exempt from pre-market review